Essential Medicines for Maternal Health: Ensuring Equitable Access for All

Through a partnership with FCI, GHV developed a set of eight briefs that outlined three lifesaving yet under-utilized maternal health medicines (oxytocin, misoprostol, and magnesium sulfate), and showcased evidence-based strategies and successful interventions that addressed key barriers to their widespread access and use.

Every two minutes, a woman dies due to pregnancy and childbirth complications—this amounts to approximately 287,000 maternal deaths each year, with 99% occurring in low- and middle-income countries.

Postpartum hemorrhage (PPH: excessive bleeding after childbirth) and pre-eclampsia/eclampsia (PE/E: dangerous elevation of blood pressure during pregnancy) are the two leading causes, accounting for nearly half of all maternal deaths. In almost all cases, these conditions are preventable or treatable. Women are dying every day, in many low- and middle-income countries, because they do not have access to essential medicines and to high-quality maternal health care.